CDK4 and breast cancer: The literature was reviewed to evaluate the use of liquid biopsy, for the analysis of tumour-derived material, in order to identify predictive biomarkers in HR+/HER2− metastatic BC (mBC) patients that were treated with CDK4/6 inhibitors plus endocrine therapy.